ALB and non-small cell lung carcinoma: Hypoalbuminemia, reported in 16% of patients treated with tepotinib, 23% with savolitinib, and 27% with amivantamab monotherapy,40,43 is a class effect of MET inhibition.74 It is also a marker of inflammation and an important prognostic factor in advanced NSCLC, as declining albumin levels can occur in the setting of increased active disease burden.75,76